Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA)

Mohamed M. Elsebaei, Haroon Mohammad, Mohamed Abouf, Nader S. Abutaleb, Youssef A. Hegazy, Adel Ghiaty, Lu Chen, Jianan Zhang, Satish R. Malwal, Eric Oldfield, Mohamed N. Seleem, Abdelrahman S. Mayhoub

Research output: Contribution to journalArticle

Abstract

The promising activity of phenylthiazoles against multidrug-resistant bacterial pathogens, in particular MRSA, has been hampered by their limited systemic applicability, due to their rapid metabolism by hepatic microsomal enzymes, resulting in short half-lives. Here, we investigated a series of phenylthiazoles with alkynyl side-chains that were synthesized with the objective of improving stability to hepatic metabolism, extending the utility of phenylthiazoles from topical applications to treatment of a more invasive, systemic MRSA infections. The most promising compounds inhibited the growth of clinically-relevant isolates of MRSA in vitro at concentrations as low as 0.5 μg/mL, and exerted their antibacterial effect by interfering with bacterial cell wall synthesis via inhibition of undecaprenyl diphosphate synthase and undecaprenyl diphosphate phosphatase. We also identified two phenylthiazoles that successfully eradicated MRSA inside infected macrophages. In vivo PK analysis of compound 9 revealed promising stability to hepatic metabolism with a biological half-life of ∼4.5 h. In mice, compound 9 demonstrated comparable potency to vancomycin, and at a lower dose (20 mg/kg versus 50 mg/kg), in reducing the burden of MRSA in a systemic, deep-tissue infection, using the neutropenic mouse thigh-infection model. Compound 9 thus represents a new phenylthiazole lead for the treatment of MRSA infections that warrants further development.

Original languageEnglish (US)
Pages (from-to)195-209
Number of pages15
JournalEuropean Journal of Medicinal Chemistry
Volume148
DOIs
StatePublished - Mar 25 2018

Fingerprint

Methicillin
Methicillin-Resistant Staphylococcus aureus
Anti-Bacterial Agents
Metabolism
undecaprenyl pyrophosphate synthetase
Infection
Liver
Diphosphates
Macrophages
Pathogens
Vancomycin
Thigh
Phosphoric Monoester Hydrolases
Cell Wall
Half-Life
Cells
Tissue
Enzymes
Growth

Keywords

  • Antibiotic resistance
  • C. elegans
  • MRSA
  • Multi-drug resistance
  • VRSA

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Alkynyl-containing phenylthiazoles : Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA). / Elsebaei, Mohamed M.; Mohammad, Haroon; Abouf, Mohamed; Abutaleb, Nader S.; Hegazy, Youssef A.; Ghiaty, Adel; Chen, Lu; Zhang, Jianan; Malwal, Satish R.; Oldfield, Eric; Seleem, Mohamed N.; Mayhoub, Abdelrahman S.

In: European Journal of Medicinal Chemistry, Vol. 148, 25.03.2018, p. 195-209.

Research output: Contribution to journalArticle

Elsebaei, MM, Mohammad, H, Abouf, M, Abutaleb, NS, Hegazy, YA, Ghiaty, A, Chen, L, Zhang, J, Malwal, SR, Oldfield, E, Seleem, MN & Mayhoub, AS 2018, 'Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA)', European Journal of Medicinal Chemistry, vol. 148, pp. 195-209. https://doi.org/10.1016/j.ejmech.2018.02.031
Elsebaei, Mohamed M. ; Mohammad, Haroon ; Abouf, Mohamed ; Abutaleb, Nader S. ; Hegazy, Youssef A. ; Ghiaty, Adel ; Chen, Lu ; Zhang, Jianan ; Malwal, Satish R. ; Oldfield, Eric ; Seleem, Mohamed N. ; Mayhoub, Abdelrahman S. / Alkynyl-containing phenylthiazoles : Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA). In: European Journal of Medicinal Chemistry. 2018 ; Vol. 148. pp. 195-209.
@article{d79b8f17afd849caba8eff154fd9c4fa,
title = "Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA)",
abstract = "The promising activity of phenylthiazoles against multidrug-resistant bacterial pathogens, in particular MRSA, has been hampered by their limited systemic applicability, due to their rapid metabolism by hepatic microsomal enzymes, resulting in short half-lives. Here, we investigated a series of phenylthiazoles with alkynyl side-chains that were synthesized with the objective of improving stability to hepatic metabolism, extending the utility of phenylthiazoles from topical applications to treatment of a more invasive, systemic MRSA infections. The most promising compounds inhibited the growth of clinically-relevant isolates of MRSA in vitro at concentrations as low as 0.5 μg/mL, and exerted their antibacterial effect by interfering with bacterial cell wall synthesis via inhibition of undecaprenyl diphosphate synthase and undecaprenyl diphosphate phosphatase. We also identified two phenylthiazoles that successfully eradicated MRSA inside infected macrophages. In vivo PK analysis of compound 9 revealed promising stability to hepatic metabolism with a biological half-life of ∼4.5 h. In mice, compound 9 demonstrated comparable potency to vancomycin, and at a lower dose (20 mg/kg versus 50 mg/kg), in reducing the burden of MRSA in a systemic, deep-tissue infection, using the neutropenic mouse thigh-infection model. Compound 9 thus represents a new phenylthiazole lead for the treatment of MRSA infections that warrants further development.",
keywords = "Antibiotic resistance, C. elegans, MRSA, Multi-drug resistance, VRSA",
author = "Elsebaei, {Mohamed M.} and Haroon Mohammad and Mohamed Abouf and Abutaleb, {Nader S.} and Hegazy, {Youssef A.} and Adel Ghiaty and Lu Chen and Jianan Zhang and Malwal, {Satish R.} and Eric Oldfield and Seleem, {Mohamed N.} and Mayhoub, {Abdelrahman S.}",
year = "2018",
month = "3",
day = "25",
doi = "10.1016/j.ejmech.2018.02.031",
language = "English (US)",
volume = "148",
pages = "195--209",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Alkynyl-containing phenylthiazoles

T2 - Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA)

AU - Elsebaei, Mohamed M.

AU - Mohammad, Haroon

AU - Abouf, Mohamed

AU - Abutaleb, Nader S.

AU - Hegazy, Youssef A.

AU - Ghiaty, Adel

AU - Chen, Lu

AU - Zhang, Jianan

AU - Malwal, Satish R.

AU - Oldfield, Eric

AU - Seleem, Mohamed N.

AU - Mayhoub, Abdelrahman S.

PY - 2018/3/25

Y1 - 2018/3/25

N2 - The promising activity of phenylthiazoles against multidrug-resistant bacterial pathogens, in particular MRSA, has been hampered by their limited systemic applicability, due to their rapid metabolism by hepatic microsomal enzymes, resulting in short half-lives. Here, we investigated a series of phenylthiazoles with alkynyl side-chains that were synthesized with the objective of improving stability to hepatic metabolism, extending the utility of phenylthiazoles from topical applications to treatment of a more invasive, systemic MRSA infections. The most promising compounds inhibited the growth of clinically-relevant isolates of MRSA in vitro at concentrations as low as 0.5 μg/mL, and exerted their antibacterial effect by interfering with bacterial cell wall synthesis via inhibition of undecaprenyl diphosphate synthase and undecaprenyl diphosphate phosphatase. We also identified two phenylthiazoles that successfully eradicated MRSA inside infected macrophages. In vivo PK analysis of compound 9 revealed promising stability to hepatic metabolism with a biological half-life of ∼4.5 h. In mice, compound 9 demonstrated comparable potency to vancomycin, and at a lower dose (20 mg/kg versus 50 mg/kg), in reducing the burden of MRSA in a systemic, deep-tissue infection, using the neutropenic mouse thigh-infection model. Compound 9 thus represents a new phenylthiazole lead for the treatment of MRSA infections that warrants further development.

AB - The promising activity of phenylthiazoles against multidrug-resistant bacterial pathogens, in particular MRSA, has been hampered by their limited systemic applicability, due to their rapid metabolism by hepatic microsomal enzymes, resulting in short half-lives. Here, we investigated a series of phenylthiazoles with alkynyl side-chains that were synthesized with the objective of improving stability to hepatic metabolism, extending the utility of phenylthiazoles from topical applications to treatment of a more invasive, systemic MRSA infections. The most promising compounds inhibited the growth of clinically-relevant isolates of MRSA in vitro at concentrations as low as 0.5 μg/mL, and exerted their antibacterial effect by interfering with bacterial cell wall synthesis via inhibition of undecaprenyl diphosphate synthase and undecaprenyl diphosphate phosphatase. We also identified two phenylthiazoles that successfully eradicated MRSA inside infected macrophages. In vivo PK analysis of compound 9 revealed promising stability to hepatic metabolism with a biological half-life of ∼4.5 h. In mice, compound 9 demonstrated comparable potency to vancomycin, and at a lower dose (20 mg/kg versus 50 mg/kg), in reducing the burden of MRSA in a systemic, deep-tissue infection, using the neutropenic mouse thigh-infection model. Compound 9 thus represents a new phenylthiazole lead for the treatment of MRSA infections that warrants further development.

KW - Antibiotic resistance

KW - C. elegans

KW - MRSA

KW - Multi-drug resistance

KW - VRSA

UR - http://www.scopus.com/inward/record.url?scp=85042067391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042067391&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2018.02.031

DO - 10.1016/j.ejmech.2018.02.031

M3 - Article

C2 - 29459278

AN - SCOPUS:85042067391

VL - 148

SP - 195

EP - 209

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -